- Novel treatment strategies for chronic myeloid leukemiaChristopher A Fausel
Hematology Oncology Bone Marrow Transplant, Indiana University Cancer Center, Indianapolis, IN 46202, USA
Am J Health Syst Pharm 63:S15-20; quiz S21-2. 2006..Mutations of the BCR-ABL kinase domain, a common mechanism of resistance to imatinib in CML, are discussed...
- Targeted chronic myeloid leukemia therapy: Seeking a cureChristopher Fausel
Hematology Oncology BMT, Indiana University Cancer Center, 550 North University Boulevard, Indianapolis, IN 46202, USA
Am J Health Syst Pharm 64:S9-15. 2007..This article focuses on imatinib, how it has altered CML therapy, clinical trials that are the basis for its efficacy, and adverse effects associated with its current clinical use...
- Targeted chronic myeloid leukemia therapy: seeking a cureChristopher Fausel
Indiana University, Cancer Center, Indianapolis, IN, USA
J Manag Care Pharm 13:8-12. 2007..BCR-ABL inhibitors, such as imatinib, are proof that targeting specific genetic mutations associated with cancer yields a high degree of efficacy with minimal toxicity...